The US Food and Drug Administration’s approval of Amylyx Pharmaceuticals, Inc.’s amyotrophic lateral sclerosis drug Relyvrio (sodium phenylbutyrate/taurursodiol) has brought new focus to when the agency will accept confirmatory evidence to support approval on the basis of a single adequate and well-controlled trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?